Post

New research · Ophthalmology
Ophthalmology and therapy · 2d
Cohort studyOphthalmology and therapy · 2026

Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration.

Federico Beretta, Giovanni Scalabrin, Edoardo Balduzzi … Giuseppe Querques
Read paper
OphthalmologyCohort study

About one-third of eyes gained meaningful vision after 1 year of faricimab treatment

Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration.

Federico Beretta … Giuseppe Querques
Ophthalmology and therapy · 2026
Background

The purpose of this study was to report 1-year real-world outcomes of faricimab for the treatment of macular neovascularization secondary to age-related macular degeneration (nAMD).

Methods

This was a retrospective, longitudinal study including 132 eyes with nAMD (27% treatment-naïve, 73% switchers) treated with faricimab following a treat-and-extend protocol.

n = 132 eyes
36%
Results
36%
more than a third had noticeably better vision after one year
n = 132 eyes
More results

After the loading phase, both BCVA (from 0.40 ± 0.33 to 0.35 ± 0.34 LogMAR) and central macular thickness (from 403 ± 135 to 317 ± 108 um) improved significantly (p = 0.014 and p > 0.001 respectively).

More results

Predictors of good response were lower BCVA and absence of type 3 macular neovascularization (macular neovascularization) at baseline and lower central macular thickness after loading phase.

Approximately 60% of patients achieved ≥ Q12-week dosing.

Treatment-naïve patients achieved higher extension rates (82% ≥ Q12).

“
Conclusion · 1 of 2

In our real-world practice, faricimab effectively controls nAMD, offering significant anatomical benefits and visual stability with extended dosing intervals. Approximately 80% of treatment-naïve patients maintained ≥ Q12-week schedules.

Conclusion · 2 of 2

Early anatomical response, defined by reduction in central macular thickness and absence of exudative signs on structural optical coherence tomography (optical coherence tomography), emerged as a clinically relevant prognostic factor for 1-year outcomes.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving